- Rufer CE, Bub A, Moseneder J, Winterhalter P, Sturtz M, Kulling SE: Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study. Am J Clin Nutr. 2008 May;87(5):1314-23. doi: 10.1093/ajcn/87.5.1314. [PubMed:18469255 ]
- Shinkaruk S, Durand M, Lamothe V, Carpaye A, Martinet A, Chantre P, Vergne S, Nogues X, Moore N, Bennetau-Pelissero C: Bioavailability of glycitein relatively to other soy isoflavones in healthy young Caucasian men. Food Chem. 2012 Dec 1;135(3):1104-11. doi: 10.1016/j.foodchem.2012.03.135. Epub 2012 May 22. [PubMed:22953831 ]
- Vergne S, Titier K, Bernard V, Asselineau J, Durand M, Lamothe V, Potier M, Perez P, Demotes-Mainard J, Chantre P, Moore N, Bennetau-Pelissero C, Sauvant P: Bioavailability and urinary excretion of isoflavones in humans: effects of soy-based supplements formulation and equol production. J Pharm Biomed Anal. 2007 Mar 12;43(4):1488-94. doi: 10.1016/j.jpba.2006.10.006. Epub 2006 Nov 15. [PubMed:17110073 ]
- Jackson RL, Greiwe JS, Desai PB, Schwen RJ: Single-dose and steady-state pharmacokinetic studies of S-equol, a potent nonhormonal, estrogen receptor beta-agonist being developed for the treatment of menopausal symptoms. Menopause. 2011 Feb;18(2):185-93. [PubMed:21341397 ]